|
ST PHARM is a contract development and manufacturing organization (CDMO) specializing in gene therapy and nucleic acid-based therapeutics. The company provides CDMO services for oligonucleotides, small-molecule APIs, and mRNA therapeutics, including the development of 5' capping technologies and lipid nanoparticle (LNP) delivery systems. ST PHARM also engages in proprietary drug discovery through a virtual R&D model, with pipeline candidates including the HIV treatment STP0404 (Pirmitegravir) and the oncology agent STP1002 (Basroparib). The company operates subsidiaries and partners such as VERNAGEN, Levatio Therapeutics, and AnaPath Services to support its integrated value chain from research to commercial manufacturing. Founded in 1983 as Samchully Pharm and joined the Dong-A Solbio Group in 2010, ST PHARM serves global pharmaceutical and biotechnology clients with cGMP-certified facilities in Korea. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage stpharm.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
oligonucleotide cdmo, mrna therapeutics, small-molecule api, gene therapy, lnp technology, 5' capping, sgrna, hiv treatment, oncology, vaccine development, virtual r&d, STP0404, Pirmitegravir, STP1002, Basroparib, STP2104, SmartCap, STLNP, VERNAGEN, Levatio Therapeutics, AnaPath Services, AnaPath Research, Quantoom Bioscience, Evonik Industries, CEPI, Multiverse Pharma, Genevant
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 10.0% |
| ROI | 9.3% |
| ROIC | 8.6% |
| Profit margin | 16.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 45.1% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 54.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 331.681B | 273.751B | 284.992B | 249.322B | 165.642B | 124.109B | 93.257B | 97.738B | 202.8B | 200.362B | 138.052B | 96.54B |
| Net profit | 54.992B | 34.712B | 19.581B | 18B | 3.312B | -12.147B | -18.529B | -9.268B | 44.997B | 61.426B | 25.189B | 5.466B |
| Free cash flow | -33.082B | 26.646B | -41.946B | -53.448B | -44.522B | -37.924B | -36.737B | -16.399B | 26.742B | 34.75B | 13.719B | -16.602B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 18B | 29.9B | 15.9B | 35.7B | 45.4B | 62.9B | 94.2B | 121B | 67.8B | 96.7B |
| ↳ YoY growth | +35.8% | +66.4% | -47.0% | +125.2% | +27.3% | +38.5% | +49.7% | +28.0% | -43.7% | +42.5% |
| ↳ 5y CAGR | +28.0% | +28.5% | +25.8% | +50.0% | +13.7% | +16.3% | ||||
| Other receivables (KRW) | — | 115M | — | — | — | — | — | — | — | — |
| Borrowings, current (KRW) | 19.5M | 19.5M | 3.4B | 19.5M | 4.78B | 15B | 114B | 29.2B | 72.2B | 76.5B |
| Borrowings, non-current (KRW) | 137M | 117M | 97.5M | 15.1B | 126B | — | 16.7B | 160B | 43.3B | 0.00 |
| Bonds payable (KRW) | — | — | — | — | — | — | 85.9B | 151B | — | — |
| Lease liabilities (KRW) | — | — | 1.91B | 896M | 6.81B | 1.07B | 3.67B | 3.18B | 2.67B | 2.18B |
| Cash and deposits (KRW) | 55.2B | 72.3B | 47.7B | 12.8B | 38.6B | 39.2B | 50.2B | 50.1B | 63.4B | 30.5B |
| Intangible assets (KRW) | 1.08B | 1.21B | 1.41B | 8B | 10B | 12.6B | 12.5B | 13.5B | 16.5B | 17B |
| Right-of-use assets (KRW) | — | — | 0.00 | 888M | 1.31B | 1.1B | 3.63B | 3.1B | 2.57B | 2.09B |
| Net debt (borrowings + leases - cash) (KRW) | -55.1B | -72.2B | -42.3B | 3.17B | 98.6B | -23.1B | 84.3B | 142B | 54.7B | 48.2B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 50.8B | 54.4B | 10.8B | -30.5B | -20.9B | 7.27B | 7.03B | 1.3B | 109B | 14B |
| Purchases of property, plant and equipment (KRW) | -16B | -27.7B | -27.2B | -6.22B | -17B | -51.8B | -60.5B | -43.2B | -82.8B | -47.1B |
| Purchases of intangible assets (KRW) | -4.48M | -40.3M | -146M | -92.8M | -455M | -126M | -185M | -199M | -419M | -214M |
| Dividends paid (cash effect) (KRW) | -2.95B | -9.24B | -9.33B | -9.33B | — | — | -9.4B | -9.4B | -9.4B | -10.1B |
| Interest paid (cash effect) (KRW) | -1.57B | -94.4M | — | -76.4M | -435M | -448M | -930M | -1.33B | -817M | -578M |
| Income taxes paid (cash effect) (KRW) | -15.3B | -21.9B | -7.51B | 297M | -10.9M | 827M | -2.87B | -2.12B | -4.96B | -8.74B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 34.7B | 26.7B | -16.5B | -36.8B | -38.4B | -44.6B | -53.6B | -42.1B | 26.2B | -33.3B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 58.2B | 45.7B | -10.2B | -18.9B | -12.7B | — | 19.5B | 19.4B | 32.3B | 55.8B |
| Comprehensive income to owners (KRW) | 58.2B | 45.7B | 0.00 | -18.9B | -11.7B | 4.8B | 19.8B | 21.2B | 34.5B | 56.1B |
| Reported | Mar 30, 2018 | Aug 14, 2018 | Mar 15, 2021 | Mar 15, 2021 | Mar 15, 2021 | Mar 15, 2024 | Aug 14, 2025 | Aug 14, 2025 | Aug 14, 2025 | Jun 2, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
-
01Who we are
-
02Our record
-
03Newsroom
-
04Contact
-
Ko
HOMEPublicPR (Public Relations)News roomAll
-
Science & Technology
-
CDMO위탁생산개발
-
CRO위탁임상서비스
-
R&D연구개발
-
About
-
Public
-
PR (Public Relations)
-
IR (Investor Relations)
-
ESG
Public
All
-
PR (Public Relations)
-
IR (Investor Relations)
All
Oct 28, 2026
[안내] 에스티팜, 미국 글로벌제약사와 261억원 규모 올리고핵산치료제 원료의약품 공급계약 체결
-
에스티팜이 미국의 글로벌제약사와 신규 CDMO 프로젝트 2건 총 1,965만 달러 (약 261억원, 전일자 최종고시 매매기준율 1,327원/USD 적용) 규모 올리고핵산치료제 원료의약품 공급계약을 체결했습니다.
-
해당 신규 프로젝트 2건은 각각 1,310만 달러 (납기 '27.12.31), 664만 달러 (납기 '27.10.30) 규모로 모두 글로벌 임상 2상이 진행 중입니다. 고객사와의 비밀유지 협약에 따라 적응증 등은 공개하지 않있습니다.
HOMEPublicPR (Public Relations)News roomAll
-
Science & Technology
-
CDMO위탁생산개발
-
CRO위탁임상서비스
-
R&D연구개발
-
About
-
Public
-
PR (Public Relations)
-
IR (Investor Relations)
-
ESG
© 2026 ST Pharm. All rights reserved.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding ST PHARM
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.07% | 1,759 | $ 92.059K | Nov 16, 2026 |
| DFEM | 0.01% | 12,789 | $ 700.754K | Nov 12, 2026 |
| DEXC | 0.01% | 336 | $ 18.411K | Nov 12, 2026 |
| DFAE | 0.00% | 6,784 | $ 371.719K | Nov 12, 2026 |
| DFSE | 0.00% | 281 | $ 15.397K | Nov 12, 2026 |
| DFAX | 0.00% | 5,026 | $ 275.392K | Nov 12, 2026 |
| AVEM | 0.00% | 4,811 | $ 251.787K | Nov 16, 2026 |
| AVSE | 0.00% | 36 | $ 1,884.09 | Nov 16, 2026 |